Miastenia gravis: diagnóstico farmacológico pelo teste da neostigmina

Abreu, Elvira B; Ferreira, Alberto Affonso; Dores, André Braga das.
Arq. Inst. Penido Burnier ; 34(2): 97-9, jul. 1992. ilus
Artículo en Portugués | LILACS | ID: lil-150543

Documentos relacionados

  1. Subclinical involvement of eye movements detected by video-based eye tracking in myasthenia gravis.
  2. Early-Onset Myasthenia Gravis Following COVID-19 Vaccination.
  3. Juvenile Generalized Myasthenia Gravis: Presented as Unilateral Blepharoptosis and Successfully Managed with Pulse Intravenous Methylprednisolone.
  4. Pathophysiological basis in the management of myasthenia gravis: a mini review.
  5. Clinical characteristics and treatment outcomes in patients with double-seronegative myasthenia gravis.
  6. Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study.
  7. Concordance between patient- and physician-reported Myasthenia Gravis Activities of Daily Living (MG-ADL) scores.
  8. EYE MYASTHENIA IN A YOUNG TOGOLESE: ABOUT A CASE AND LITERATURE REVIEW.
  9. Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors.
  10. [Myasthenia Gravis - Update].